RADIOPHARM THERANOSTICS

NASDAQ: RADX / ASX: RAD

Annual General Meeting

NOVEMBER 20 , 2025

Notice & Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation is not a prospectus or other disclosure document under the *Corporations Act 2001* (Cth) and will not be lodged with the Australian Securities and Investments Commission. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this presentation, you should observe such restrictions as any non- compliance with these restrictions could contravene applicable securities laws (see the section captioned ‘International offer restrictions’). In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change.

Investments Highlights

<u>Clinical Stage</u> Company Advancing First-in-Class Radiopharmaceuticals

- Five priority molecules; 4 Therapeutics (PD-L1; HER2; B7H3; KLK3) and 1 Diagnostics (Brain Mets)

Secure Supply Chain

- Redundant and secure radioisotopes supply chains (Lu177 & Tb161)

Strategic Partnerships

- Co-development agreement with Lantheus Holdings and Joint Venture with THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Making Cancer History®

Experienced management team

Financials

- Cash runway to Q1 2027

RAD
RADIOPHARM THERANOSTICS

Company Priorities – Five *first-in-class* radiopharmaceutical molecules

	PROGRAM	TARGET & MOLECULE	INDICATION	ISOTOPE	PRECLINICAL	PHASE I	PHASE IIA	PHASE IIB	November updates in yellow
IMAGING TRIAL	**RAD101**	**Short Chain Fatty Acid** (small molecule)	Brain Mets	F18					Phase 2b in 5 US centers, **NCT06777433** 15 patients dosed / 30 patients total (11/'25) **Expect to complete enrollment 1Q26**
THERAPEUTIC TRIALS	**RAD204**	**PD-L1** (nanobody)	PD-L1+ solid tumors	Lu177					Phase 1 in 4 AUS centers, **NCT06305962** DL1 at 30mCi & DL2 at 60mCi completed DL3 at 90mCi recruiting **Expect trial completion in 2026**
	RAD202	**HER2** (nanobody)	HER2+ solid tumors	Lu177					Phase 1 in 5 AUS centers **NCT06824155** DL 1 at 30mCi completed DL 2 at 75mCi recruiting **Expect trial completion in 2026**
	RV01	**B7-H3** (mAb)	B7-H3+ solid tumors	Lu177			THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Making Cancer History®		IND approval 07/2025 **NCT07189871** Phase I in 4 US centers, FPFV expected Q4 2025 **First two Dose Levels data in mid-2026**
	RAD402	**KLK3** (mAb)	Advanced prostate cancer	Tb161					Ethics approval received (11/2025) Phase 1 study in 4 AUS centers **First two Dose Levels data in mid-2026**

RAD
RADIOPHARM THERANOSTICS

B7-H3, B7 homolog 3; F18, fluorine-18; HER2, human epidermal growth factor receptor 2; KLK3, kallikrein-related peptidase 3; Lu177, lutetium-177; mAb, monoclonal antibody; PD-L1, programmed death ligand-1; Tb161, terbium-161.

RAD 101 Imaging: Clinical Development

- Phase IIb imaging study currently recruiting in five centers in USA: 50% enrolment achieved
- No competitor identified; RAD 101 is the only PET agent in clinical development for Brain Mets
- Large Total addressable market: 300,000 new subjects diagnosed every year (US only)

PRECLINICAL	PHASE I	PHASE IIa	PHASE IIb	PHASE III
	UK	UK	USA	
	24 pts	22 pts	30 pts	150 pts

RADIOPHARM THERANOSTICS

* NCT06777433

Clinical Data from Phase IIb

- Images from n=3 subjects in the ongoing study released
- Showing increased metabolic activity in areas with equivocal MRI findings (suspected relapse)
- N=15 subjects dosed as of 11/17/2025

Next Steps

Phase IIb

- 11 patient data to be released by Q1 2026
- Trial completion N=30/30 pts by Q1 2026
- Phase 2b readout in the first half of 2026

Phase III

- FDA Meeting to align on Phase III - mid 2026
- Phase III start – Q4 2026

RAD101 COMMERCIAL POTENTIAL: USD$ >500m yearly sales (USA only)

Third largest imaging molecule after Pilarify (Lantheus) & Illucix (Telix)



Note: [1]In the scenario where RAD101 is the sole product on the market, the peak market share of 100% has been adjusted with a 5% discount factor to account for potential deviations in HCP behavior, such as non-adherence to guidelines or shifts in the SoC. Source: Definitive Healthcare; Primary research; Alira Health analysis.

RADIOPHARM THERANOSTICS

RADIOPHARM THERANOSTICS

Molecule: **177Lu-RAD204**

Targeting MoA: **PD-L1**

Therapeutic for: **PD-L1+ TUMORS**

Phase 1 Trial Design

^{177}Lu-anti-PD-L1 single domain AB in metastatic solid tumors

Primary Objectives

- Safety and tolerability of ^{177}Lu-RAD204
- Recommended ph2 dose of ^{177}Lu-RAD204$_{tr}$

Study Design

BOIN for escalation / de-escalation.
Population: History of PD-L1 positive (≥1%) metastatic tumors

Imaging Phase 0

Biodistribution, dosimetry and PK with low dose ^{177}Lu-RAD204$_{im}$ in organs of interest and tumor

Therapeutic Phase 1

^{177}Lu-RAD204$_{tr}$ dose escalation

	Dose Level	Dose
Phase 0 (Imaging Period with ^{177}Lu-RAD204$_{im}$)	**Imaging dose**	10 (0.37 GBq)
Phase I (Treatment Period with ^{177}Lu-RAD204$_{tr}$)	**Therapeutic DL1**	30 mCi (1.1. GBq)
	DL2	60 mCi (2.2 GBq)
	DL3	90 mCi (3.3 GBq)
	DL4	

PROGRAM	TARGET & MOLECULE	INDICATION	Dx/Tx	ISOTOPE	1ST HALF 2024	2ND HALF 2024	1ST HALF 2025	2ND HALF 2025	MID 2026
RAD 204 NCT06305962	PD-L1 (Nanobody)	PD-L1+ Solid Tumors	Therapy	Lu177	Ethics Approval Received ☑	• First Patient Treated • Approval for Trial Expansion in 6 Tumor Types ☑	1 Cohort Completed ☑	2 Cohorts Completed first 6 pts data released ☑	Phase 1 dose escalation completed ☐

RADIOPHARM THERANOSTICS

BOIN, Bayesian optimal interval; DL, dose level; GBq, gigabecquerel; mCi, millicurie; PD-L1, programmed death ligand-1; PK, pharmacokinetics; TBD, to be determined.

Clinical data Phase I

- First (30mCi) and Second Cohort (60mCi) completed, and 6 patient data released.
- Tumor uptake confirmed in all the treated subjects. No tumor reduction above 30% achieved at the first two dose levels
- The safety profile has been very favorable, with few adverse events and no related SAEs observed.

- Currently recruiting Third Cohort (90mCi).

RADIOPHARM THERANOSTICS

*One patient (Patient 003-009) is not DLT-evaluable (consent withdrawal due to personal reasons)
NSCLC, non-small cell lung cancer; PD-1, programmed death-1; PDL-1, programmed death ligand-1; PFS, progression-free survival.

Tumor Uptake| Significant increase at DL2 vs DL1

COHORT#1

	Average Absorbed dose at 30 mCi
Patients	Dose (Gy), with PVC[1]
#1	0.56
#2	0.45
#3	0.21
	0.41

COHORT#2

	Average Absorbed dose at 60 mCi
Patients	Dose (Gy), with PVC[1]
#4	1.0
#5	0.5
#6	2.8
	1.43

RAD
RADIOPHARM THERANOSTICS

RADIOPHARM THERANOSTICS

Molecule: **177Lu-RAD202**

Targeting MoA: **HER2**

Therapeutic for: **HER2+ TUMORS**

Phase 1 Trial Design

'HEAT' Trial (HER2 Antibody Therapy with Lutetium-177) in subjects with HER2+ advanced solid tumors

Primary Objectives (Phase 1, Treatment):

- Safety and tolerability of ^{177}Lu-RAD202
- Recommended ph2 dose of ^{177}Lu-RAD202

Population:
Her2+ (IHC, ISH) a/m solid tumors

Phase 0 Imaging:
Biodistribution, PK and radiation dosimetry of ^{177}Lu-RAD202$_{im}$ in organs of interest and tumor lesions

Phase I Therapeutic:
^{177}Lu-RAD202$_{tr}$ dose escalation

	Dose Level	Dose
Phase 0 (Imaging Period with ^{177}Lu- RAD202$_{im}$)	**Imaging dose**	10 mCi
Phase I (Treatment Period with ^{177}Lu- RAD202$_{tr}$)	**Therapeutic DL1**	30 mCi (1.1 GBq)
	DL2	75 mCi (2.7 GBq)
	DL3+	TBD

PROGRAM	TARGET & MOLECULE	INDICATION	Dx/Tx	ISOTOPE	1ST HALF 2024	2ND HALF 2024	1ST HALF 2025	2ND HALF 2025	1ST HALF 2026	2ND HALF 2026
RAD 202	HER2 (Nanobody)	HER2+ Solid Tumors	Therapy	Lu177	Preclinical Studies Completed ☑	Ethics Approval (Dec 2024) ☑	First Patient dosed ☑	2 Cohorts Completed ☐	2 Cohorts Data Release ☐	Phase 1 Dose escalation completed ☐

RADIOPHARM THERANOSTICS

a/m, advanced or metastatic; DL, dose level; GBq, gigabecquerel; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; Lu177, lutetium-177; mCi, millicurie; PK, pharmacokinetics; TBD, to be determined.

Clinical Data Phase I

- First Cohort completed (30 mCi), with 3 Patient data released
- Significant tumor uptake observed
- The safety profile very favorable, with few low-grade adverse events and no SAEs observed thus far

- Currently recruiting Cohort #2 at 75mCi

RADIOPHARM THERANOSTICS

[1]Zhao et al, Br Canc Res (2024); Zhao et al, Mol Pharmaceut (2021)
99mTc, technetium-99m; 177Lu, lutetium-177; mCi, millicurie; NSCLC, non-small cell lung cancer; PD-1, programmed death-1; PD-L1, programmed death ligand-1; PFS, progression-free survival.

RAD

RADIOPHARM THERANOSTICS

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

Molecule: **RV01/BetaBart**

Targeting MoA: **B7H3**

Therapeutic for: **Multiple Tumor Types**

RV01 (Betabart) Key Milestones

1. Phase I therapeutic trial IND received in July 2025
2. Basket Phase I therapeutic trial to start by the end of 2025

▲ ACHIEVED

▲ Future Milestone

PROGRAM	TARGET & MOLECULE	INDICATION	Dx/Tx	ISOTOPE	*2ND HALF 2024*	*1ST HALF 2025*	*2ND HALF 2025*	*1ST HALF 2026*
RV01	**B7-H3** (mAb)	**Solid Tumors**	**Therapy**	**Lu177**	▲ PRE-IND FDA meeting	▲ IND submission	▲ IND approval ▲ First Patient Dosed	▲ First two cohorts Data release

RAD RADIOPHARM THERANOSTICS

RAD

RADIOPHARM THERANOSTICS

Memorial Sloan Kettering Cancer Center

Molecule: **RAD 402 – 161Tb**

Targeting MoA: **KLK3**

Therapeutic for: **PROSTATE CANCER**

RAD 402 – mAb targeting KLK3 in Prostate Cancer

1. RAD 402 is a humanized IgG_1 internalized by prostate cells, specifically binding KLK3 with high affinity

2. RAD 402 has highly specific expression in the prostate (compared to PSMA, which is expressed in multiple other organs)

KLK3 is expressed only in prostate. PSMA has more off-target affinity



RADIOPHARM THERANOSTICS

RAD 402 – Key Milestones

1. Ethics Committee approval in Q4 2025
2. Phase I therapeutic trial in Australia to start in Q4 2025

PROGRAM	TARGET & MOLECULE	INDICATION	Dx/Tx	ISOTOPE	*2ND HALF 2024*	*1ST HALF 2025*	*2ND HALF 2025*
RAD402	KLK3 (mAb)	PROSTATE	Therapy	Tb161	▲ BioD & Tox studies completed	▲ CMC completed	▲ Ethics Committee Approval ▲ Phase I start

▲ ACHIEVED

▲ Future Milestone

RAD
RADIOPHARM THERANOSTICS

Company Priorities – Five *first-in-class* radiopharmaceutical molecules

	PROGRAM	TARGET & MOLECULE	INDICATION	ISOTOPE	PRECLINICAL / PHASE I / PHASE IIA / PHASE IIB	November updates in yellow
IMAGING TRIAL	**RAD101**	**Short Chain Fatty Acid** (small molecule)	Brain Mets	F18		Phase 2b in 5 US centers, **NCT06777433** 15 patients dosed / 30 patients total (11/'25) **Expect to complete enrollment 1Q26**
THERAPEUTIC TRIALS	**RAD204**	**PD-L1** (nanobody)	PD-L1+ solid tumors	Lu177		Phase 1 in 4 AUS centers, **NCT06305962** DL1 at 30mCi & DL2 at 60mCi completed DL3 at 90mCi recruiting **Expect trial completion in 2026**
	RAD202	**HER2** (nanobody)	HER2+ solid tumors	Lu177		Phase 1 in 5 AUS centers **NCT06824155** DL 1 at 30mCi completed DL 2 at 75mCi recruiting **Expect trial completion in 2026**
	RV01	**B7-H3** (mAb)	B7-H3+ solid tumors	Lu177	THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Making Cancer History®	IND approval 07/2025 **NCT07189871** Phase I in 4 US centers, FPFV expected Q4 2025 **First two Dose Levels data in mid-2026**
	RAD402	**KLK3** (mAb)	Advanced prostate cancer	Tb161		Ethics approval received (11/2025) Phase 1 study in 4 AUS centers **First two Dose Levels data in mid-2026**

RAD RADIOPHARM THERANOSTICS

B7-H3, B7 homolog 3; F18, fluorine-18; HER2, human epidermal growth factor receptor 2; KLK3, kallikrein-related peptidase 3; Lu177, lutetium-177; mAb, monoclonal antibody; PD-L1, programmed death ligand-1; Tb161, terbium-161.

RAD

RADIOPHARM THERANOSTICS

Thank You

www.radiopharmtheranostics.com